The U.S. Supreme Court issues a temporary administrative stay that restores access to mifepristone, including delivery through the mail and access via telehealth and pharmacies. The change pauses a lower-court ruling that had reinstated an FDA requirement requiring patients to visit a health care provider in person before obtaining the medication. Several outlets report that a federal appeals court ruling issued on Friday had imposed new limits on prescribing mifepristone through mail-order channels, effectively threatening broader access nationwide. The Supreme Court order is signed by Justice Samuel Alito and blocks the appeals court decision from taking effect while further legal proceedings continue. Coverage across outlets describes the order as temporary and focused on maintaining current access arrangements for now rather than resolving the underlying legal dispute. One outlet also characterizes the affected FDA-related access pathways as those used in a large share of pregnancy terminations in the U.S., though figures are not consistently detailed across sources. Overall, the reporting agrees that the Supreme Court’s action preserves the availability of mifepristone by mail, for the time being, against a court order that would have tightened those distribution methods.